Cost utility of tumour necrosis factor-α inhibitors for rheumatoid arthritis: An application of bayesian methods for evidence synthesis in a markov model

PharmacoEconomics

Volumn 30, Issue 7, 2012, Pages 575-593

  Nguyen, Christine M ^a   Bounthavong, Mark ^a   Mendes, Margaret A S ^a   Christopher, Melissa L D ^a   Tran, Josephine N ^a   Kazerooni, Rashid ^a   Morreale, Anthony P ^a  

^a VA SAN DIEGO HEALTHCARE SYSTEM   (United States)

Author keywords

Adalimumab; Certolizumab pegol; Cost utility; Disease modifying ; ntirheumatics; Etanercept; Golimumab; Infliximab; Methotrexate; Rheumatoid ; rthritis; Tumour necrosis factor ; lpha inhibitors.

Indexed keywords

ADALIMUMAB; CERTOLIZUMAB PEGOL; ETANERCEPT; GOLIMUMAB; INFLIXIMAB; METHOTREXATE; TOCILIZUMAB; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

ARTICLE; BAYES THEOREM; COST UTILITY ANALYSIS; DISEASE SEVERITY; DRUG COST; HUMAN; MONOTHERAPY; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; REMISSION; RHEUMATOID ARTHRITIS; TREATMENT DURATION; TREATMENT RESPONSE;

ARTHRITIS, RHEUMATOID; BAYES THEOREM; COST-BENEFIT ANALYSIS; DRUG THERAPY, COMBINATION; HEALTH RESOURCES; HUMANS; IMMUNOGLOBULIN G; IMMUNOSUPPRESSIVE AGENTS; MARKOV CHAINS; METHOTREXATE; MODELS, ECONOMIC; QUALITY-ADJUSTED LIFE YEARS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECEPTORS, TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84862165188     PISSN: 11707690     EISSN: 11792027     Source Type: Journal    
DOI: 10.2165/11594990-000000000-00000     Document Type: Article

References (65)

1. Arthritis Foundation. Rheumatoid arthritis [online]. Available from URL:http://www.arthritis.org/disease-center.php? disease-id=31 [Accessed 2009 Oct 5]
2. National Center for Chronic Disease Prevention and Health Promotion. Arthritis type:overview [online]. Available from URL:http://www.cdc.gov/ arthritis/basics/rheumatoid. htm [Accessed 2009 Oct 5]
3. Rindfleisch JA, Muller D. Diagnosis and management of rheumatoid arthritis. Am Fam Physician 2005; 72 (6):1037-47 (Pubitemid 43093259)
4. Hootman JM, Helmick CG, Schappert SM, et al. Magnitude and characteristics of arthritis and other rheumatic conditions on ambulatory medical care visits, United States, 1997. Arthritis Rheum 2002; 47 (6):571-81 (Pubitemid 35461308)
5. American College of Rheumatology Subcommittee on Rheumatoid Arthritis Guidelines. Guidelines for the management of rheumatoid arthritis:2002 update. Arthritis Rheum 2002; 46 (2):328-46
6. Saag KG, Teng GG, Patkar NM, et al. American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. Arthritis Rheum2008; 59 (6):762-84 (Pubitemid 351847559)
7. Smolen JS, Landewé R, Breedvled FC, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann Rheum Dis 2010; 69 (6):964-75
8. Michaud K, Messer J, Choi HK, et al. Direct medical costs and their predictors in patients with rheumatoid arthritis: A three-year study of 7,527 patients. Arthritis Rheum 2003; 48 (10):2750-62 (Pubitemid 37280602)
9. Barbieri M, Wong JB, Drummond M. The cost effectiveness of infliximab for severe treatment-resistant rheumatoid arthritis in the UK. Pharmacoeconomics 2005; 23 (6):607-18 (Pubitemid 40994128)
10. Brennan A, Bansback N, Reynolds A, et al. Modelling the cost-effectiveness of etanercept in adults with rheumatoid arthritis in the UK. Rheumatology 2004; 43 (1):62-72 (Pubitemid 38088370)
11. Welsing PM, Severens JL, Hartman M, et al. Modeling the 5-year cost effectiveness of treatment strategies including tumor necrosis factor-blocking agents and leflunomide for treating rheumatoid arthritis in the Netherlands. Arthritis Rheum 2004; 51 (6):964-73 (Pubitemid 39648190)
12. Spalding JR, Hay J. Cost effectiveness of tumour necrosis factor- A inhibitors as first-line agents in rheumatoid arthritis. Pharmacoeconomics 2006; 24 (12):1221-32 (Pubitemid 44901677)
13. Davies A, Cifaldi MA, Segurado OG, et al. Costeffectiveness of sequential therapy with tumor necrosis factor antagonists in early rheumatoid arthritis. J Rheumatol 2009; 36 (1):16-26
14. Wailoo AJ, Bansback N, Brennan A, et al. Biologic drugs for rheumatoid arthritis in the Medicare program: A costeffectiveness analysis. Arthritis Rheum 2008; 58 (4):939-46 (Pubitemid 351563994)
15. Chung CP, Thompson JL, Koch GG, et al. Are American College of Rheumatology 50%response criteria superior to 20% criteria in distinguishing active aggressive treatment in rheumatoid arthritis clinical trials reported since 1997? A meta- Analysis of discriminant capacities. Ann Rheum Dis 2006; 65 (1):1602-7 (Pubitemid 44799672)
16. Pincus T, Stein CM. ACR20:clinical or statistical significance? Arthritis Rheum 1999; 42 (8); 1572-6
17. Genentech, Inc.Actemra (tocilizumab injection for intravenous infusion):US prescribing information. San Francisco (CA):Genentech, Inc., 2010
18. Emery P, Keystone E, Tony HP, et al. IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to antitumour necrosis factor biologics:results from a 24-week multicentre randomised placebo-controlled trial. Ann Rheum Dis 2008; 67 (11):1516-23
19. Hoyert DL, Heron MP, Murphy SL, et al. Deaths:final data for 2003. Natl Vital Stat Rep 2006; 54 (13):1-120
20. Sonnenberg FA, Beck JR. Markov models in medical decision making: A practical guide. Med Decis Making 1993; 13 (4):322-38 (Pubitemid 24013155)
21. Braithwaite RS, Meltzer DO, King JT, et al. What does the value of modern medicine say about the $50,000 per quality- Adjusted life-year decision rule? Med Care 2008; 46 (4):349-56
22. TreeAge Software [computer program]. Release 1.0.2. Williamstown (MA):TreeAge Software, Inc, 2009
23. Chen DY, Chou SJ, Hsieh TY, et al. Randomized, doubleblind, placebo-controlled comparative study of human anti-TNF antibody adalimumab in combination with methotrexate and methotrexate alone in Taiwanese patients with active rheumatoid arthritis. J Formos Med Assoc 2009; 108 (4):310-9
24. Keystone EC, Kavanaugh AF, Sharp JT, et al. Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: A randomized, placebo-controlled, 52-week trial. Arthritis Rheum 2004; 50 (5):1400-11 (Pubitemid 38608061)
25. Weinblatt ME, Keystone EC, Furst DE, et al. Adalimumab, a full human anti-tumor necrosis factor monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: The ARMADA trial. Arthritis Rheum 2003; 48 (1):35-45 (Pubitemid 36091645)
26. Smolen J, Landewé RB, Mease P, et al. Efficacy and safety of certolizumab pegol plus methotrexate in active rheumatoid arthritis: The RAPID 2 study - A randomised controlled trial. Ann Rheum Dis 2009; 68 (6):797-804
27. Keystone E, van der Heijde D, Mason Jr D, et al. Certolizumab pegol plus methotrexate is significantly more effective than placebo plus methotrexate in active rheumatoid arthritis:findings of a fifty-two-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel- group study. Arthritis Rheum 2008; 58 (11):3319-29
28. Lan JL, Chou SJ, Chen DY, et al. A comparative study of etanercept plus methotrexate and methotrexate alone in Taiwanese patients with active rheumatoid arthritis: A 12-week, double-blind, randomized, placebo-controlled study. J Formos Med Assoc 2004; 103 (8):618-23
29. Klareskog L, van der Heijde D, de Jager JP, et al. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis:double-blind randomised controlled trial. Lancet 2004; 363 (9410):675-81 (Pubitemid 38296553)
30. Weinblatt ME, Kremer JM, Bankhurst AD, et al. A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med 1999; 340 (4):253-9 (Pubitemid 29063266)
31. Keystone EC, Genovese MC, Klareskog L, et al. Golimumab, a human antibody to tumour necrosis factor- A given by monthly subcutaneous injections, in active rheumatoid arthritis despite methotrexate therapy: The GO-FORWARD study. Ann Rheum Dis 2009; 68 (6):789-96
32. Kay J, Matteson EL, Dasgupta B, et al. Golimumab in patients with active rheumatoid arthritis despite treatment with methotrexate. Arthritis Rheum 2008; 58 (4):964-75
33. Westhovens R, Yocum D, Han J, et al. The safety of infliximab, combined with background treatments, among patients with rheumatoid arthritis and various comorbidities: A large, randomized, placebo-controlled trial. Arthritis Rheum 2006; 54 (4):1075-86 (Pubitemid 43672920)
34. Lipsky PE, van der Heijde DM, St. Clair EW, et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis: Anti-tumor necrosis factor trial in rheumatoid arthritis with concomitant therapy study group. N Engl J Med 2000; 343 (22):1594-602
35. Jansen JP, Crawford B, Bergman G, et al. Bayesian metaanalysis of multiple treatment comparisons: An introduction to mixed treatment comparisons. Value Health 2008; 11 (5):956-64
36. Ades AE, Sculpher M, Sutton A, et al. Bayesian methods for evidence synthesis in cost-effectiveness analysis. Pharmacoeconomics 2006; 24 (1):1-19 (Pubitemid 43197227)
37. Spiegelhalter DJ, Myles JP, Jones DR, et al. Methods in health service research: An introduction to Bayesian methods in health technology assessment. BMJ 1999; 319 (7208):508-12 (Pubitemid 29391365)
38. Spiegelhalter D, Thomas A, Best N, et al. WinBUGS user manual:version 1.4. Cambridge:MRC Biostatistics Unit, 2003
39. Lambert PC, Sutton AJ, Burton PR, et al. How vague is vague? A simulation study of the impact of the use of vague prior distributions in MCMC using WinBUGS. Stat Med 2005; 24 (15):2401-28 (Pubitemid 41093922)
40. Smith TC, Spiegelhalter DJ, Thomas A. Bayesian approaches to random-effects meta- Analysis: A comparative study. Stat Med 1995; 14 (24):2685-99 (Pubitemid 26014258)
41. Gelman A. Prior distributions for variance parameters in hierarchical models. Bayesian Anal 2006; 1:151-33
42. Gelman A, Rubin DB. Inferences from iterative simulation using multiple sequences. Stat Sci 1992; 7:457-72
43. CODA [computer program]. Version 0.30. Cambridge:MRC Biostatistics Unit, 1996
44. Chiou CF, Weisman M, Sherbourne CD, et al. Measuring preference weights for American College of Rheumatology response criteria for patients with rheumatoid arthritis. J Rheumatol 2005; 32 (12):2326-9 (Pubitemid 41780641)
45. Gold MR, Siegel JE, Russell LB, et al., editors. Costeffectiveness in health and medicine. New York (NY):Oxford University Press, 1996
46. Fleming T, editor. Red book:pharmacy's fundamental reference. Montvale (NJ):Thomson PDR, 2009
47. US House of Representatives Committee on Oversight and Government Reform. Private Medicare drug plans:high expenses and low rebates increase the costs of Medicare drug coverage. 2007 Oct [online]. Available from URL:http://www. allhealth.org/briefingmaterials/housemajority staff-965.pdf [Accessed 2011 Apr 1]
48. Centers for Medicare and Medicaid Services. Hospital outpatient prospective payment system(OPPS):April addendum - HCPCS codes [online]. Available from URL:http://www. cms.gov/apps/ama/license.asp?file=/ hospitaloutpatientpps/ downloads/2009-April-Addendum-B-040109.zip [Accessed 2010 Aug 4]
49. Healthcare Cost and Utilization Project. HCUP overview. Rockville (MD):Agency for Healthcare Research and Quality, 2009 Nov [online]. Available from URL:http:// www.hcup-us.ahrq.gov/overview.jsp [Accessed 2010 Jul 12]
50. Centocor Ortho Biotech, Inc. Remicade (infliximab lyophilized concentrate for intravenous injection):US prescribing information. Malvern (PA):Centocor Ortho Biotech, Inc., 2009
51. Briggs AH. Handling uncertainty in cost-effectivenessmodels. Pharmacoeconomics 2000; 17 (5):479-500
52. Briggs A, Sculpher M, Claxton K. Decision modelling for health economic evaluation. New York:Oxford University Press, 2006
53. Fenwick E, O'Brien BJ, Briggs A. Cost-effectiveness acceptability curves:facts, fallacies and frequently asked questions. Health Econ 2004; 13 (5):405-15 (Pubitemid 38660390)
54. Fenwick E, Claxton K, Sculpher M. Representing uncertainty: The role of cost-effectiveness acceptability curves. Health Econ 2001; 10 (8):779-87 (Pubitemid 34041389)
55. Fiddelers AA, Dirksen CD, Dumoulin JC, et al. Costeffectiveness of seven IVF strategies:results of a Markov decision- Analytic model. Hum Reprod 2009; 24 (7):1648-55
56. Barton GR, Briggs AH, Fenwick EA. Optimal costeffectiveness decisions: The role of the cost-effectiveness acceptability curve (CEAC), the cost-effectiveness acceptability frontier (CEAF), and the expected value of perfect information (EVPI). Value Health 2008; 11 (5):886-97
57. Deighton C, Hyrich K, Ding T, et al. BSR and BHPR rheumatoid arthritis eligibility criteria for the first biological therapy. Rheumatology 2010 [online]. Available from URL:http://www.rheumatology.org.uk/includes/documents/ cm-docs/2010/r/2-ra-guidelines-on-eligibility-criteria-for-the-first-biological- therapy.pdf. [Accessed 2012 Mar 25]
58. van der Heijde DM, van't Hof MA, van Riel PL, et al. Judging disease activity in clinical practice in rheumatoid arthritis:first step in the development of a disease activity score. Ann Rheum Dis 1990; 49 (11):916-20 (Pubitemid 20360757)
59. Prevoo ML, van't Hof MA, Kuper HH, et al. Modified disease activity scores that include twenty-eight-joint counts:development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995; 38 (1):44-8
60. Barbieri M, Drummond MF, Puig Junoy J, et al. Critical appraisal of pharmacoeconomic studies comparing TNF- A antagonists for rheumatoid arthritis treatment. Expert Rev Pharmacoecon Outcomes Res 2007; 7 (6):613-26
61. Lekander I, Borgström F, Svarvar P, et al. Costeffectiveness of real-world infliximab use in patients with rheumatoid arthritis in Sweden. Int J Tech Assess Health Care 2010; 26 (1):54-61
62. Hyrich KL, Lunt M, Watson KD, et al. Outcomes after switching from one anti-tumor necrosis factor a agent to a second anti-tumor necrosis factor a agent in patients with rheumatoid arthritis:results from a large UK national cohort study. Arthritis Rheum 2007; 56 (1):13-20 (Pubitemid 46106174)
63. Brennan A, Bansback N, Nixon R, et al. Modelling the cost effectiveness of TNF- A antagonists in the management of rheumatoid arthritis:results from the British Society for Rheumatology Biologics Registry. Rheumatology 2007; 46 (8):1345-5
64. Birnbaum H, Pike C, Kaufman R, et al. Societal cost of rheumatoid arthritis patients in the US. Curr Med Res Opin 2010; 26 (1):77-90
65. Centers for Disease Control and Prevention. Update:direct and indirect costs of arthritis and other rheumatic conditions - United States, 1997. MMWR Morb Mortal Wkly Rep 2004; 53 (18):338-9